A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication

Trial Profile

A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2016.
    • 01 Dec 2015 Planned number of patients changed from 580 to 605 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top